Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal anti...
Oct 27, 2025, 7:05 AM EDT - 13 hours ago
Oct 9, 2025, 8:00 AM EDT - 18 days ago
Oct 8, 2025, 6:04 AM EDT - 19 days ago
Oct 8, 2025, 5:00 AM EDT - 19 days ago
Sep 2, 2025, 7:05 AM EDT - 7 weeks ago
RPRX
Aug 26, 2025, 7:05 AM EDT - 2 months ago
Aug 12, 2025, 7:05 AM EDT - 2 months ago
Jul 28, 2025, 1:42 PM EDT - 3 months ago
Jun 20, 2025, 4:15 PM EDT - 4 months ago
Jun 16, 2025, 3:44 AM EDT - 4 months ago
Jun 15, 2025, 10:44 AM EDT - 4 months ago
Jun 12, 2025, 6:17 PM EDT - 4 months ago
Jun 11, 2025, 10:24 AM EDT - 4 months ago
May 31, 2025, 8:55 AM EDT - 5 months ago
May 29, 2025, 7:05 AM EDT - 5 months ago
May 15, 2025, 3:10 PM EDT - 5 months ago
May 15, 2025, 7:05 AM EDT - 5 months ago
May 13, 2025, 4:20 PM EDT - 5 months ago
May 5, 2025, 2:48 PM EDT - 6 months ago
May 1, 2025, 3:08 PM EDT - 6 months ago
Apr 22, 2025, 10:37 AM EDT - 6 months ago
Apr 21, 2025, 12:33 PM EDT - 6 months ago
Apr 17, 2025, 8:00 PM EDT - 6 months ago